Fig. 4 | Signal Transduction and Targeted Therapy

Fig. 4

From: Neoadjuvant nivolumab with or without platinum-doublet chemotherapy based on PD-L1 expression in resectable NSCLC (CTONG1804): a multicenter open-label phase II study

Fig. 4

Circulating tumor DNA (ctDNA) and survival outcomes. a Swimmer plot depicted events in patients with baseline ctDNA testing (n = 38). The left column displays pathologcial responses and clinical characteristics. Each bar represents one patient. b Patient survival according to ctDNA/MRD status at T2 (after the completion of neoadjuvant treatment) and T3 (1 month after surgery, prior to adjuvant treatment). Negative, ctDNA/MRD, assessed as negativity at both T2 and T3; Positive, ctDNA/MRD+, assessed as positivity at either T2 or T3. ASC adenosquamous carcinoma, LUAD lung adenocarcinoma, LUSC lung squamous carcinoma, MPR major pathological response, N nivolumab monotherapy, N/C nivolumab plus chemotherapy, pCR pathologic complete response

Back to article page